Abstract
It has been widely underlined that both gynaecological malignancies and urogynaecological disorders are often associated with high stress and have a negative impact on the quality of life and psychological well-being of women affected. Knowledge of the pelvic anatomy is crucial in recommending and carrying out the least harmful although successful treatment. Subsequent chemoradiation may also induce or exaggerate troublesome symptoms. The aim of the study was to establish the frequency of urogynaecological symptoms (stress urinary incontinence, urgency, pelvic organ prolapse) and to assess the impact of surgical treatment and additional oncological therapy: pelvic radiation, chemoradiation, chemotherapy, on the prevalence of pelvic floor dysfunctions (PFD) and lower urinary tract symptoms (LUTS) in patients suffering from gynecological malignancies. The study group consisted of 160 women, diagnosed with gynaecological malignancy, who underwent surgical treatment and additional adjuvant treatment as necessary. To establish the QoL and prevalence of PFD Urinary Distress Inventory-6 (UDI-6), Incontinence Impact Questionnaire 7 (II-Q7), King’s Health Questionnaire (KHQ) and the SF-36 Questionnaire were used. Herein, 69 patients reported urinary incontinence (UI) and 67 reported symptoms of pelvic organ prolapse (POP). After the six months follow-up UI was found in 78 patients, 25 patients showed de novo symptoms, 65 patients reported POP and 10 patients demonstrated de novo POP. Our data show that urogynaecological symptoms are not correlated with the type of malignancy, but with the extensiveness of surgery.
Highlights
The common embryological, topographic and functional origin of the genitourinary tract implies the potential being present for collective adverse reactions during or after management of oncological condition [1]
Apart from the fact that knowledge of the anatomy and topography of the genitourinary tract is crucial in recommending and carrying out the least harmful successful treatment, it must be kept in mind that subsequent radio-chemotherapy may induce or exaggerate troublesome symptoms [2,3]
Considering the genitourinary tract, worldwide demographic trends lead to Jt.hCelinc.oMncedlu. 2s0i2o0n, 9t,h2a80t4morbidity and mortality related to malignant conditions will increase the bu2rodfe1n2 of post-treatment pelvic floor disorders (PFD) and lower urinary tract symptoms (LUTS) [4]
Summary
The common embryological, topographic and functional origin of the genitourinary tract implies the potential being present for collective adverse reactions during or after management of oncological condition [1]. Oncological therapy can lead to adverse effects of long-term related treatment that often significantly and negatively affect the quality of life (QoL) among female patients. Considering the genitourinary tract, worldwide demographic trends lead to the conclusion among female patients. 2s0i2o0n, 9t,h2a80t4morbidity and mortality related to malignant conditions will increase the bu2rodfe1n2 of post-treatment pelvic floor disorders (PFD) and lower urinary tract symptoms (LUTS) [4]. Considering the genitourinary tract, worldwide demographic trends lead to Jt.hCelinc.oMncedlu. This is tahlsaot mcoonrfbiirdmiteydabnydtmheorItnatleitrynaretiloanteadl OtonmcoalloiggnicaanltCcoonmdmitiiottnese,wwilhl iicnhcrcelaasiemtshtehbautrtdheentroefnpdoostf-tinrecaidtmenencet poef lgvyicneflcooolrogdiicsaolrmdearlsig(nPaFnDc)ieasnadmloowngeryuoruinngarwy otrmacetns(y2m0–p4t4omyesa(rLsUofTaSg)e[)4i]s. InAteltrhnoautigohnaPl OFDncoalnodgicLalUCToSmamreitteceo,mwmhiocnh calamimonsgthaotntchoelotgreicnadl opfainticeindtesn, cbeootfhgysntiellcorleomgiacianl munadliegrneasnticmieastaemd aonndg ynoout npgrowpoermlyenex(p20o–s4tu4lyaeteadrsboyf pagatei)einstisnacnredahsienagltshycsaterme patriocvalildye[r5s][.6A,7l]t.hMouogrheoPvFeDr, abnodthLLUUTTSSaraencdoPmFmDoanreamasosnogcioantecdolwogitihcallopwaetirenQtos,Lb, owthorssteillprseymchaion-suoncdiaelrefustnimctiaotnedinagnadnndoet mprootpioenrlayl epxrpoobsletumlaste[d8–b1y0]p. aAtienntins taenrdnahteioanltahl ccalraesspirfoicvaitdioerns [i6n,c7l]u. dMesormeoovreer,tbhoatnh L10U0TSmaanlidgnPaFnDt adriesaeasssoecsi,abteudt wstuitdhileoswoenr eQtiooLlo, gwyo, rpsaethposygcehnoe-ssisocainadl futrnecattimonenintgaarendlimemiteodtiotonatlhposroebolcecmusrr[i8n–g10m].oAstnfrienqteurennattliyon[1a]l. cNlaesvseirfitchaetlieosns,itnhcelurdeseesamrcohroenthPaFnD1a0n0dmLaUliTgnSaanmt odnisgeoasnecso,lbougitcsatlusduirevsivoonrestsiotillol greym, paainthsovgeernyelsimisiatendd. tTrheaetpmreimntaaryrealiimmiotef dthteostthuodsye wocacsutroriensgtambloissht ftrheequfreenqtulyen[1cy]. oNf euvreorgtyhnealeescso,ltohgeicraelsesyarmchptoonmPsFaDmaonndg LfeUmTaSleamonocnogloogniccaollopgaitciaelnstus rsvuivffoerrsinsgtilflrroemmagiynnsevceorlyogliimcailtemd.alTighneapnrciimesa.rAy asiemcoonfdthareystauidmy wwaass ttoo easstsaebslsisthhethime fpraecqtuoefnscuyrogficuarlotgreyantameceonltoagnicdaladsydmitipotnoaml sonamcoolonggicfaeml tahleeraopnycoolnogtihcealppraevtiaelnetnscseuofffePriFnDg farnodmLgUyTnSecionloogniccoallomgiaclaigl nsuanrvciievso.rAs astescioxnmdaornythaismfowlloaws t-oupas.sess the impact of surgical treatment and additional oncological therapy on the prevalence of PFD and LUTS in oncological survivors at six m2.oMntahtesrfioalllsowan-udpM. ethods
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
